# A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

> **NCT03568318** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 1533 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Upadacitinib
- **DRUG:** Topical corticosteroids (TCS)

## Key facts

- **NCT ID:** NCT03568318
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-09
- **Primary completion:** 2021-02-16
- **Final completion:** 2030-10-23
- **Target enrollment:** 1533 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568318, "A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03568318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*